ACS Med Chem Lett. 2025 Jan 23;16(3):363-365. doi: 10.1021/acsmedchemlett.5c00011. eCollection 2025 Mar 13.
ABSTRACT
This patent application pertains to macrocyclic peptides, generally represented by Formula I. These compounds exhibit selective binding to tumor necrosis factor receptor 1 (TNFR1) and hold the potential for mitigating the progression of diseases or disorders associated with TNFα/TNFR1 signaling, including autoimmune and inflammatory conditions.
PMID:40104799 | PMC:PMC11912260 | DOI:10.1021/acsmedchemlett.5c00011